MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2026-03-31, SLN had -$5,603K decrease in cash & cash equivalents over the period. -$15,603K in free cash flow.

Cash Flow Overview

Change in Cash
-$5,603K
Free Cash flow
-$15,603K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Redemption of term deposits
    • General and administrative expen...
    • Share-based compensation expense
    • Others
Negative Cash Flow Breakdown
    • Purchase of term deposits
    • (decrease)/increase in trade and...
    • Other income, net
    • Others

Cash Flow
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Revenue
-103 ---
Cost of sales
-192 ---
General and administrative expenses
-11,584 ---
Tax expense
-11 ---
Net loss
-14,957 -11,770 -20,958 -55,884
Depreciation expense
72 77 81 154
Income tax expense
-0 1 10
Amortization expense
34 36 75 132
Share-based compensation expense
2,447 -86 2,535 5,625
Net foreign exchange impacts
25 -230 918 -11,710
Other income, net
519 880 770 1,830
Decrease in trade receivables
0 -30 -62 -932
Decrease/(increase) in other current assets
-931 1,741 -5,331 -2,426
(increase)/decrease in r&d benefit receivable
209 -190 2,492 -6,343
Decrease in other long-term assets
0 -257 -3,387 -14
(decrease)/increase in trade and other payables
-2,949 -3,576 2,883 -3,385
Increase in contract liabilities
-404 -32 -88 -214
Increase in operating lease liabilities
-24 -22 -20 -126
Net cash used in operations
-15,603 -17,287 -10,891 -34,093
Redemption of term deposits
74,427 20,440 71,478 26,558
Purchase of term deposits
64,427 73,778 20,186 72,449
Purchase of property, plant and equipment
0 0 3 52
Net cash provided by/(used in) investing activities
10,000 -53,338 51,289 -45,943
Proceeds from issue of ordinary shares
0 0 0 15
Net cash provided by financing activities
0 0 0 15
Decrease in cash and cash equivalents
-5,603 -70,625 40,398 -80,021
Cash and cash equivalents at start of period
11,277 0 121,330 -
Effect of exchange rate fluctuations on cash and cash equivalents held
-17 -129 324 -
Cash and cash equivalents, end of period
5,657 11,277 82,031 -
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Redemption of term deposits$74,427K Net cash providedby/(used in) investing...$10,000K Canceled cashflow$64,427K Decrease in cash and cashequivalents-$5,603K Canceled cashflow$10,000K Share-based compensationexpense$2,447K Decrease/(increase) in other currentassets-$931K Depreciation expense$72K Amortization expense$34K Purchase of term deposits$64,427K Net cash used inoperations-$15,603K Canceled cashflow$3,484K General andadministrative expenses-$11,584K Cost of sales-$192K Tax expense-$11K Net loss-$14,957K (decrease)/increase in trade andother payables-$2,949K Canceled cashflow$11,787K Other income, net$519K Increase in contractliabilities-$404K (increase)/decrease in r&d benefitreceivable$209K Net foreignexchange impacts$25K Increase in operatinglease liabilities-$24K something is missing-$26,641K Revenue-$103K

Silence Therapeutics plc (SLN)

Silence Therapeutics plc (SLN)